company background image
ALTME logo

TME Pharma ENXTPA:ALTME Stock Report

Last Price

€0.31

Market Cap

€8.7m

7D

8.8%

1Y

-68.3%

Updated

27 Mar, 2024

Data

Company Financials

ALTME Stock Overview

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.

ALTME fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

TME Pharma N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TME Pharma
Historical stock prices
Current Share Price€0.31
52 Week High€2.20
52 Week Low€0.19
Beta1.53
1 Month Change-6.27%
3 Month Change31.38%
1 Year Change-68.28%
3 Year Change-99.27%
5 Year Change-99.60%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Will NOXXON Pharma (EPA:ALNOX) Spend Its Cash Wisely?

Dec 20
Will NOXXON Pharma (EPA:ALNOX) Spend Its Cash Wisely?

We're Keeping An Eye On NOXXON Pharma's (EPA:ALNOX) Cash Burn Rate

Sep 06
We're Keeping An Eye On NOXXON Pharma's (EPA:ALNOX) Cash Burn Rate

Is NOXXON Pharma (EPA:ALNOX) In A Good Position To Invest In Growth?

May 19
Is NOXXON Pharma (EPA:ALNOX) In A Good Position To Invest In Growth?

NOXXON Pharma (EPA:ALNOX) Is In A Good Position To Deliver On Growth Plans

Feb 01
NOXXON Pharma (EPA:ALNOX) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

ALTMEFR BiotechsFR Market
7D8.8%1.0%0.4%
1Y-68.3%-1.8%9.6%

Return vs Industry: ALTME underperformed the French Biotechs industry which returned -1.8% over the past year.

Return vs Market: ALTME underperformed the French Market which returned 10.6% over the past year.

Price Volatility

Is ALTME's price volatile compared to industry and market?
ALTME volatility
ALTME Average Weekly Movement17.5%
Biotechs Industry Average Movement5.8%
Market Average Movement4.2%
10% most volatile stocks in FR Market9.8%
10% least volatile stocks in FR Market2.2%

Stable Share Price: ALTME's share price has been volatile over the past 3 months.

Volatility Over Time: ALTME's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
199713Aram Mangasarianhttps://www.tmepharma.com

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.

TME Pharma N.V. Fundamentals Summary

How do TME Pharma's earnings and revenue compare to its market cap?
ALTME fundamental statistics
Market cap€8.74m
Earnings (TTM)-€8.46m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALTME income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€8.46m
Earnings-€8.46m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.30
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-1,354.0%

How did ALTME perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.